| Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer NA Rizvi, MD Hellmann, A Snyder, P Kvistborg, V Makarov, JJ Havel, ... Science 348 (6230), 124-128, 2015 | 8023 | 2015 |
| SARS-CoV-2 infection of the oral cavity and saliva N Huang, P Pérez, T Kato, Y Mikami, K Okuda, RC Gilmore, CD Conde, ... Nature medicine 27 (5), 892-903, 2021 | 692 | 2021 |
| Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: a case series AV Rapkiewicz, X Mai, SE Carsons, S Pittaluga, DE Kleiner, JS Berger, ... EClinicalMedicine 24, 2020 | 559 | 2020 |
| Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner RB Holmgaard, D Zamarin, Y Li, B Gasmi, DH Munn, JP Allison, ... Cell reports 13 (2), 412-424, 2015 | 455 | 2015 |
| ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity JA Moral, J Leung, LA Rojas, J Ruan, J Zhao, Z Sethna, A Ramnarain, ... Nature 579 (7797), 130-135, 2020 | 267 | 2020 |
| Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers FJ Lowery, S Krishna, R Yossef, NB Parikh, PD Chatani, N Zacharakis, ... Science 375 (6583), 877-884, 2022 | 196 | 2022 |
| Non-conventional inhibitory CD4+ Foxp3− PD-1hi T cells as a biomarker of immune checkpoint blockade activity R Zappasodi, S Budhu, MD Hellmann, MA Postow, Y Senbabaoglu, ... Cancer cell 33 (6), 1017-1032. e7, 2018 | 151 | 2018 |
| Breast cancers are immunogenic: immunologic analyses and a phase II pilot clinical trial using mutation-reactive autologous lymphocytes N Zacharakis, LM Huq, SJ Seitter, SP Kim, JJ Gartner, S Sindiri, VK Hill, ... Journal of Clinical Oncology 40 (16), 1741, 2022 | 85 | 2022 |
| Immune checkpoint blockade in combination with stereotactic body radiotherapy in patients with metastatic pancreatic ductal adenocarcinoma C Xie, AG Duffy, G Brar, S Fioravanti, D Mabry-Hrones, M Walker, ... Clinical Cancer Research 26 (10), 2318-2326, 2020 | 69 | 2020 |
| Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy RB Holmgaard, A Brachfeld, B Gasmi, DR Jones, M Mattar, T Doman, ... Oncoimmunology 5 (7), e1151595, 2016 | 67 | 2016 |
| Quantification of tumor-derived cell free DNA (cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies P Momtaz, E Pentsova, O Abdel-Wahab, E Diamond, D Hyman, ... Oncotarget 7 (51), 85430, 2016 | 66 | 2016 |
| The new era of cancer immunotherapy: manipulating T-cell activity to overcome malignancy DN Khalil, S Budhu, B Gasmi, R Zappasodi, D Hirschhorn-Cymerman, ... Advances in cancer research 128, 1-68, 2015 | 63 | 2015 |
| Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor–engineered T cells targeting common p53 neoantigens in human solid tumors SP Kim, NR Vale, N Zacharakis, S Krishna, Z Yu, B Gasmi, JJ Gartner, ... Cancer immunology research 10 (8), 932-946, 2022 | 61 | 2022 |
| T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants D Hirschhorn, S Budhu, L Kraehenbuehl, M Gigoux, D Schröder, A Chow, ... Cell 186 (7), 1432-1447. e17, 2023 | 60 | 2023 |
| Integrated single-cell atlases reveal an oral SARS-CoV-2 infection and transmission axis N Huang, P Perez, T Kato, Y Mikami, K Okuda, RC Gilmore, ... MedRxiv, 2020.10. 26.20219089, 2020 | 55 | 2020 |
| In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors DN Khalil, N Suek, LF Campesato, S Budhu, D Redmond, RM Samstein, ... The Journal of clinical investigation 129 (8), 3435-3447, 2019 | 47 | 2019 |
| Liver histology: diagnostic and prognostic features B Gasmi, DE Kleiner Clinics in liver disease 24 (1), 61-74, 2020 | 39 | 2020 |
| Neoantigen identification and response to adoptive cell transfer in anti–PD-1 naïve and experienced patients with metastatic melanoma ST Levi, AR Copeland, S Nah, JS Crystal, GD Ivey, A Lalani, M Jafferji, ... Clinical cancer research 28 (14), 3042-3052, 2022 | 23 | 2022 |
| 31st annual meeting and associated programs of the society for immunotherapy of cancer (Sitc 2016): Part two: National harbor, md, USA. 9-13 November 2016 C Ager, M Reilley, C Nicholas, T Bartkowiak, A Jaiswal, M Curran, ... Journal for ImmunoTherapy of Cancer 4, 107-221, 2016 | 12 | 2016 |
| Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation JDWPBC Parisa Momtaz, James J. Harding, Charlotte Ariyan, Daniel G. Coit ... Oncotarget 8, 105000-105010, 2017 | 11 | 2017 |
Taha MerghoubAssociate Professor, MSKبريد إلكتروني تم التحقق منه على mskcc.org
